"[Drug] manufacturers have an increasing interest ...

... in pursuing pay-for-performance contracts to mitigate ongoing pricing criticisms and secure additional competitive advantage from their peers when negotiating with payers....Important to note is that new resources, business models, and data assets are coming online to bridge the gap between manufacturers and payers to facilitate these performance contracts in a compliant and transparent manner."

— Rujul Desai, a vice president at Avalere Health, told AIS's Specialty Pharmacy News.